Sharad A. Ghamande, MD of Medical College of Georgia discusses the unmet need for cervical cancer and the promising data coming out of the AIM2CERV trial, especially for patients with high risk of recurring disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
AIM2CERV: Identifying Patients with High Risk for Recurring Disease in Cervical Cancer
